burosumab

Burosumab is a fully human monoclonal IgG1 antibody that targets and inhibits fibroblast growth factor 23 (FGF23). By binding to FGF23, it blocks its biological activity, which restores renal phosphate reabsorption and increases serum concentrations of active vitamin D (1,25-dihydroxyvitamin D). This leads to increased intestinal absorption of phosphate and calcium, supporting bone mineralization. Burosumab is primarily indicated for the treatment of X-linked hypophosphatemia (XLH) in adults and children aged 6 months or older, as well as tumor-induced osteomalacia (TIO) in adults and children aged 2 years or older when tumors cannot be surgically removed. The drug was developed by Kyowa Kirin[3][6][7].

Brand names

Crysvita

Other names

burosumab-twza